Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellaVision ABCHIX:CEVIS 99 EV-to-OCF is 20.37 as of Aug. 11, 2026, which is 51% below its 10-year median of 41.60. GuruFocus rates CHIX:CEVIS with a GF Score™ of 99/100 and a GF Value™ of kr201.48. The stock has 2 warning signs investors should review. Among 853 Medical Devices & Instruments companies, CellaVision AB ranks worse than 75.97% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, CellaVision AB's Enterprise Value is kr3,515.1 Mil.
CellaVision AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was kr172.6 Mil. Therefore, CellaVision AB's EV-to-OCF for today is 20.37.
The historical rank and industry rank for CellaVision AB's EV-to-OCF or its related term are showing as below:
CHIX:CEVIs'
s EV-to-OCF Range Over the Past 10 Years
Min: 12.98 Med: 41.6 Max: 128.11
Current: 20.37
During the past 13 years, the highest EV-to-OCF of CellaVision AB was 128.11. The lowest was 12.98. And the median was 41.60.
CHIX:CEVIs's EV-to-OCF is ranked worse than 75.97% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.85
vs CHIX:CEVIs: 20.37
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CellaVision AB's PE Ratio (TTM) for today is calculated as:
CellaVision AB's share price for today is kr160.20.
CellaVision AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr5.410.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CellaVision AB EV-to-OCF Related Terms
CellaVision AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for CellaVision AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where CellaVision AB's EV-to-OCF falls into.
CellaVision AB's current Enterprise Value is kr3,515.1 Mil.
CellaVision AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr172.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CHIX:CEVIS) has a EV-to-OCF of 20.37 as of Aug. 11, 2026. This is 51% below median its historical median of 41.60. Over the past decade, CellaVision AB's EV-to-OCF has ranged from 12.98 to 128.11. According to the industry distribution chart, CellaVision AB ranks #648 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 76%.
Is CellaVision AB's EV-to-OCF too high?
CellaVision AB's current EV-to-OCF of 20.37 is 51% below median its 10-year median of 41.60. Over the past 10 years, this metric has ranged from a low of 12.98 to a high of 128.11. The Medical Devices & Instruments industry median EV-to-OCF is 7.85. CellaVision AB's value of 20.37 is 159.5% above this industry median. Based on the distribution chart, CellaVision AB ranks #648 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, CellaVision AB has a GF Score™ of 99/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #648 out of 853 companies for EV-to-OCF. This places CellaVision AB in the lower half of its industry. The industry median EV-to-OCF is 7.85. CellaVision AB's value of 20.37 is 159.5% above this benchmark. Historically, CellaVision AB's own EV-to-OCF has ranged from 12.98 to 128.11 over the past decade. While the company's 10-year median is 41.60 vs. the industry median of 7.85, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.85, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current EV-to-OCF of 20.37 is 159.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current EV-to-OCF is 20.37, which is 51% below median its own 10-year median of 41.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current EV-to-OCF of 20.37. The stock's GF Value™ is kr201.48, compared to a current price of kr160.20 — trading 20.5% below its estimated fair value. The current EV-to-OCF is 20.37, which is 51% below median its 10-year median of 41.60 and 159.5% above the Medical Devices & Instruments industry median of 7.85. CellaVision AB's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current EV-to-OCF is 20.37 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of kr160.20 is trading 20.5% below its estimated GF Value™ of kr201.48.
Key valuation signals for CHIX:CEVIS:
EV-to-OCF: 20.37 (51% below median its 10-year median of 41.60)
GF Value™: kr201.48 vs. price of kr160.20 (20.5% below fair value)
Industry Position: 159.5% above the Medical Devices & Instruments median (#648 of 853)
No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
99GF Score
Get the complete analysis for CHIX:CEVIS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CEVIS has been successfully added to your 
